Sepsis is defined as a systemic inflammatory response in the presence of a proven or suspected infectious process 1 . There are approximately 750,000 cases of sepsis diagnosed in the United States each year. According to the Center for Disease Control, this is the tenth most common cause of mortality, accounting for 34,851 reported deaths in 2007 2 . Mortality rates as high as 70% have been reported in patients with septic shock 3 . Even though intense research is devoted to the field of infectious disease and sepsis, only a few interventions such as goaldirected therapy and activated protein C therapy have been shown to reduce mortality in septic patients.
Despite numerous attempts at novel intervention and tests to aid in earlier diagnosis and improved treatment, there has been an increased incidence of overall mortality related to sepsis, even with improvements of in-hospital mortality 4 . Statins are inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), which is a key and highly regulated enzyme in the synthesis of cholesterol. The beneficial effects of statins as potent cholesterol-lowering agents have been clearly established in cardiovascular medicine for some time, but more recently their pleiotropic effects are gaining increasing attention. The term 'pleiotropic effect' refers to the effects of statins not dependent on cholesterol reduction 5 . Definitive evidence to support the routine use of statins in patients with sepsis has not yet been elicited. Collectively, the data that do exist in humans have shown mixed results, although this data comes largely from observational trials.
The purpose of our study was to further evaluate whether statin use prior to admission decreases all cause hospital mortality in patients who have sepsis, severe sepsis, or septic shock.
SUMMARY
Despite numerous attempts at novel intervention and tests to aid in earlier diagnosis and improved treatment, there has been an increased incidence of overall mortality related to sepsis, despite improvements in in-hospital mortality. Statins have emerged as potential immunomodulatory and antioxidant agents that might impact on sepsis outcomes. Definitive evidence to support the routine use of statins in patients with sepsis has not yet been elicited. We retrospectively analysed data from patients who presented with sepsis, severe sepsis or septic shock, stratifiying them according to statin use into two groups (statin and no statin). Sequential Organ Failure Assessment was used to evaluate severity of illness. The primary outcome was hospital mortality. Secondary outcomes included intensive care unit (ICU) mortality, hospital and ICU length of stay, and mechanical ventilation and vasopressor therapy duration. Five hundred and sixty-eight patients were included. Patients with prior statin use (statin group) were older, more obese and had higher prevalence of smoking, diabetes and ischaemic heart disease. There was no difference in Sequential Organ Failure Assessment scores and mortality did not vary between the two groups (19.6 vs 16.9%). Furthermore, secondary outcomes including ICU mortality, hospital and ICU length of stay, mechanical ventilation and vasopressor duration did not differ. Multivariate analysis revealed age and Sequential Organ Failure Assessment score were independent predictors of survival, while history of statin use was not (P=0.403). This current retrospective study did not find any benefit of statin use on primary and secondary outcomes of the patients admitted to an academic hospital with sepsis.
METHODS
This is a retrospective cohort study. We conducted an analysis of patients who presented with a diagnosis of sepsis, severe sepsis or septic shock. The Internal Review Board of the University of Missouri approved the study. The study was conducted at the University of Missouri Health Center, which is a 271 bed tertiary care trauma centre, and Columbia Regional Hospital, which is a community hospital that is part of the university system. All patients who were admitted to the University of Missouri Hospitals between the years 2001 and 2007 were screened for inclusion into the study. ICD-9 coding was used to select only those patients diagnosed with infection during hospitalisation. This selected group of patients was then confirmed to have infection by either positive microbial culture or by clinical diagnosis of infection. They also had to meet criteria for systemic inflammatory response syndrome and sepsis, which was determined by individual chart review of the electronic record. Eligibility criteria for enrolment included the diagnosis of sepsis which was defined using systemic inflammatory response syndrome criteria to include the presence of infection and more than two of the following; temperature >38°C or <36°C, heart rate >90 beats per minute, respiratory rate >20 or P a CO 2 <32, white blood cells >12,000 or <4000 or bandaemia >10% 6 . Severity of illness was further defined by Sequential Organ Failure Assessment (SOFA) score 7 . Exclusion criteria included patients less than 18 years of age, pregnant women and terminally ill patients (less than a six month life expectancy).
Data collection
Collected data included age, gender, height, weight, mean arterial pressure on admission, individual values for SOFA score, low density lipoprotein levels (if available) vasopressor use and duration, and comorbidities including diabetes mellitus, ischaemic heart disease and acute respiratory distress syndrome (ARDS). ARDS was defined as per the American-European Consensus Conference definition that includes acute onset of symptoms, presence of bilateral infiltrates on chest radiographs, pulmonary artery occlusion pressure <18 mmHg in absence of clinical signs of left atrial hypertension and P a O 2 / FiO 2 ratio <200 mmHg 8 . The presence of ARDS was determined by review of data recorded during the first 24 hours of intensive care unit (ICU) admission. The SOFA score was determined during the first 24 hours of admission to the ICU, and was calculated by completion of a standardised form after a thorough review of the electronic medical record. This was done for all admissions to ICU from the emergency room, transfers from outside hospitals, or as transfers from non-ICU to ICU bed. The SOFA score for non-ICU patients was also calculated within 24 hours of admission. The SOFA score determines the extent of a person's organ function or rate of failure, and ranges from 0 to 24, with 24 as the highest severity level 7 .
Outcome measures
Primary outcome was hospital mortality defined as mortality that occurred during hospitalisation. Secondary outcomes included ICU mortality, ICU and hospital length of stay (LOS), mechanical ventilation duration and vasopressor duration. LOS was defined as the number of calendar days of stay in ICU or hospital. Mechanical ventilation duration was defined as number of calendar days on invasive mechanical ventilation. Non-invasive ventilation was not included in this measure. Vasopressor duration was defined as number of calendar days on vasopressors including any dose of noradrenaline, dopamine, phenylephrine, vasopressin or adrenaline.
Statistical analysis
Data were entered into a database (Microsoft Access 2003, Microsoft Corporation, Redmond, WA, USA). Patients were divided into a statin group if statin drugs were listed in their active medication list at time of admission to hospital. Continuation of statin therapy during hospital stay was not required to be included in the statin group. The second group consisted of patients who were not on statin medication at time of hospital admission (no-statin group). Continuous data were expressed as means or medians according to normality testing using Kolmogorov-Smirnov tests and compared using the Student T-test or the Mann-Whitney test, whichever applicable. Categorical variables were expressed as percentages and compared using the chi-square or Fisher exact tests. After completion of univariate analysis, multivariate analysis using logistic regression was performed to discern predictors of hospital survival. All variables with a P value of at least 0.1 on univariate analysis were entered in the logistic regression model. Results of this analysis were expressed as odd ratios (OR) with 95% confidence intervals (CI). Statistical significance was defined as P <0.05 and all tests were two-sided. An independent predictor was defined as any variable with P value of less than 0.05, and confidence intervals that do not include 1. Finally, a Kaplan-Meier curve was produced to depict survival times among the two groups. The log rank test was used for survival analysis.
RESULTS

Characteristics of the patients
The characteristics of the population studied are depicted in Table 1 . Females comprised 41.1% of patients in the statin-treated group. Patients using statins were older, had higher prevalence of obesity, diabetes, ischaemic heart disease and tobacco use. No significant differences in the prevalence of ARDS or the severity of the disease (evaluated by SOFA score) were found at admission among the two groups (Table 1 ). Furthermore, there was no difference in sources of sepsis between the two groups.
Outcomes
There was no difference in hospital mortality. The in-hospital mortality was 16.9 and 19.6% for the statin treated group and the non-statin group, respectively, P=0.505 (Table 2) . Similarly, the ICU and hospital LOS were not significantly different. Finally, mechanical ventilation and vasopressor durations were similar.
Survival
The Kaplan-Meier estimate for survival was not significantly different between the cohort using statins and the one not using statins (P=0.412).
Multivariate analysis
Using logistic regression, a multivariate analysis was performed to discern predictors of hospital survival (Table 3) . Age, OR 0.97 (95% CI 0.96 to 0.99), and SOFA score, OR 0.705 (95% CI 0.64 to 0.78), at admission were the only variables examined that independently predicted survival. History of statin use was not a significant predictor of hospital survival (P=0.403).
DISCUSSION
The potential role of statins in sepsis lies in their anti-inflammatory and modulatory effects. Upon inhibition of mevalonate synthesis, statins not only inhibit cholesterol synthesis but also the isoprenylation of key proteins in the inflammatory cascade. Blocking the isoprenylation of small guanosine triphosphate proteins including Ras, Rac and Rho prevents the activation of intracellular signaling cascades responsible for the generation of chemokines, cytokines, acute phase reactants and adhesion molecules 9 . Evidence in animal models has shown improvement in sepsis-induced vasoplegia as well as decreased capillary leakage after statin treatment. According to experimental animal studies, survival benefits of statins appear to be a drug class effect, and do not seem to be restricted to specific agents 10 . This study found no benefit of prior statin use in hospital or ICU mortality in those patients who present to the hospital with sepsis. We included only patients with a confirmed diagnosis of sepsis. The overwhelming inflammatory response seen in severe sepsis and septic shock does not appear to be altered by the anti-inflammatory properties of statin drugs. Evidence supports that organ dysfunction is associated with higher rates of ICU of morbidity and mortality 11, 12 . Mortality is unlikely to be affected by a single intervention, including the use of statins prior to hospitalisation.
Our findings are consistent with a study by Yang et al, except the number of patients admitted to ICU was lower in that study (n=130) as compared to our study (n=269), and their primary outcome was 30 day mortality 13 . The results of our study were also consistent with a study by Majumdar et al, which focused on statin use and outcomes of patients admitted with community-acquired pneumonia. Our population had a higher rate of admission to the ICU, 47.3 vs 18%, and higher overall mortality, 13.4 vs 10%. The higher mortality rate is reflective of the poorer prognosis expected in patients who present with sepsis compared to those with pneumonia 14 .
Our findings are in contrast to Almog et al who reported a trend towards reduction in mortality in statin users, and found a significant reduction in the rate of severe sepsis and ICU admission in those patients on statin therapy 15 . A large cohort study done in Canada by Hackman et al had similar results. In this population-based matched cohort of 69,168 patients, the incidence of sepsis was substantially lower among patients receiving statins (hazard ratio 0.81; 95% CI 0.72 to 0.91) 16 .
To date, no large randomised controlled trials have given definitive evidence to support routine use of statins in the treatment of sepsis, severe sepsis or septic shock 17 . The majority of studies to date have had retrospective design. Few have evaluated whether there was benefit in continuation of statins during hospital or ICU admission in patients with severe sepsis or septic shock. Compliance with statins over time was not determined in the majority of studies. This limits our ability to determine the duration of statin use required to provide protective benefits. The survival benefit found in other studies may be attributable to the known positive effects of statin use on cardiovascular disease, or to Type I error due to other unmeasured confounding factors.
Another explanation may be that statin use is associated with a better than expected outcome given the age and coexisting disease burden in this group. We agree with the concept of the "healthy user effect" that previous authors have proposed. This idea suggests that patients who are on statins are of higher socioeconomic status, have higher education, are more likely to have higher numbers of visits to general practitioner clinic and are more likely to be compliant with prescribed medical therapy. Collectively, these factors are thought to contribute to the improved outcomes of statin users who had infection 18 . Publication bias favouring positive results is another possible reason that the current evidence is weighted towards benefit in patients with infection and who use statins.
The strengths of our study include a large population size compared to studies with similar design. Our study was designed to specifically look at ICU and hospital mortality as it relates to admission with sepsis. In our study we determined the presence of sepsis through detailed review of electronic medical record which helped to ensure the correct diagnosis of the patient prior to being included in the data set. The percentage of patients who were statin users was consistent with previously published studies 13, 19 .
The limitations of our study include its retrospective design, with inherent weaknesses of such design such as data incompleteness and potential selection bias. For example, not all patients had adequate data to calculate SOFA scores (only 505/568 had complete data, missing 63 patients). We cannot claim that we have accounted for every confounding factor which may have an effect on survival. Although we attempted to control for potential confounders in the multivariate model, like other observational studies, unmeasured confounders cannot completely be ruled out 13, 14, 16, 19, 20 . Conversely, the lack of survival benefit seen in our study and many others could be attributed to Type II error as none of those studies are powered enough to detect true survival benefit. Adjusting for many baseline confounding factors may by itself dilute a potential survival benefit for statins.
CONCLUSION
Our study of patients with prior statin use who were admitted with sepsis showed no improvement in hospital survival. Our study and many others question the theories that link statins to survival. Our study provokes further discussion on the pleiotropic benefits of statin drugs. Until results from a large randomised, placebo-controlled trial are available, routine use of statins to prevent or treat severe forms of infection is not warranted.
